During the past decade, People's Hospital of Xinjiang Uygur Autonomous Region conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 1 clinical trials were completed, i.e. on average, 5.9% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 1 clinical trials were completed. i.e. 7.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "People's Hospital of Xinjiang Uygur Autonomous Region" #1 sponsor was "Bayer" with 2 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Shanghai Junshi Bioscience Co., Ltd." with 2 trials sponsored, "Angde Biotech Pharmaceutical Co., Ltd." with 1 trials sponsored and "Children's Hospital of Fudan University" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "People's Hospital of Xinjiang Uygur Autonomous Region" #1 collaborator was "People's Hospital of Xinjiang Uygur Autonomous Region" with 4 trials as a collaborator, "Sponsor GmbH" with 2 trials as a collaborator, "Affiliated Hospital of Qinghai University" with 1 trials as a collaborator, "Anhui Provincial Hospital" with 1 trials as a collaborator and "Beijing Hospital" with 1 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "People's Hospital of Xinjiang Uygur Autonomous Region" are "Systemic Lupus Erythematosus" (2 trials), "Active Ankylosing Spondylitis" (1 trials), "Acute Ischemic Stroke" (1 trials), "Adverse Drug Reaction" (1 trials) and "Arteriosclerosis; Extremities" (1 trials). Many other conditions were trialed in "People's Hospital of Xinjiang Uygur Autonomous Region" in a lesser frequency.

Most popular intervention types in "People's Hospital of Xinjiang Uygur Autonomous Region" are "Drug" (12 trials), "Other" (3 trials), "Biological" (2 trials), "Device" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "JS005" (2 trials), "Acarbose" (1 trials), "Albuterol Sulfate" (1 trials) and "Baricitinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "People's Hospital of Xinjiang Uygur Autonomous Region" are 18 trials for "All" genders.

Currently, there are NaN active trials in "People's Hospital of Xinjiang Uygur Autonomous Region". 1 are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in People's Hospital of Xinjiang Uygur Autonomous Region, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in People's Hospital of Xinjiang Uygur Autonomous Region, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 8 trials that are defined as “Not Applicable".